VistaGen Therapeutics (NASDAQ:VTGN) Stock Breaks Below 50 Day Moving Average – Here’s What Happened

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) crossed below its 50-day moving average during trading on Tuesday. The stock has a 50-day moving average of $0.26 and traded as low as $0.2506. VistaGen Therapeutics shares last traded at $0.2506, with a volume of 1,578,254 shares.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of VistaGen Therapeutics in a research note on Monday, August 31st. Four equities research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Reduce” and an average target price of $0.95.

VistaGen Therapeutics Price Performance

The stock’s 50-day moving average price is $0.26 and its 200 day moving average price is $0.43. The firm has a market cap of $10.93 million, a P/E ratio of -0.15 and a beta of 0.33.

VistaGen Therapeutics (NASDAQ:VTGN) last released its earnings results on Friday, August 14th. The company reported ($0.30) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.06. VistaGen Therapeutics had a negative net margin of 2,702.64% and a negative return on equity of 152.59%. The business had revenue of $1.48 million during the quarter, compared to the consensus estimate of $0.50 million. As a group, analysts forecast that VistaGen Therapeutics, Inc. will post -1.45 EPS for the current fiscal year.

Institutional Trading of VistaGen Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Seven Fleet Capital Management LP acquired a new position in VistaGen Therapeutics during the fourth quarter valued at approximately $42,000. AdvisorShares Investments LLC increased its position in shares of VistaGen Therapeutics by 10.8% during the 1st quarter. AdvisorShares Investments LLC now owns 277,110 shares of the company’s stock worth $158,000 after purchasing an additional 26,922 shares during the last quarter. Renaissance Technologies LLC raised its stake in shares of VistaGen Therapeutics by 81.2% during the 1st quarter. Renaissance Technologies LLC now owns 291,300 shares of the company’s stock worth $166,000 after purchasing an additional 130,509 shares in the last quarter. BlackRock Inc. bought a new stake in shares of VistaGen Therapeutics during the 2nd quarter worth approximately $78,000. Finally, ADAR1 Capital Management LLC acquired a new stake in shares of VistaGen Therapeutics in the 2nd quarter valued at approximately $79,000. Institutional investors own 78.39% of the company’s stock.

About VistaGen Therapeutics

VistaGen Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders, with an emphasis on anxiety, depression and related conditions. The company is headquartered in South San Francisco, California, and conducts its development activities primarily in the United States.

VistaGen’s lead product candidate is fasedienol, also known as PH94B, an investigational neuroactive nasal spray being developed for the treatment of social anxiety disorder and other anxiety-related conditions.